{"doi":"10.1016/j.jtho.2021.07.021","title":"The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up","abstract":"INTRODUCTION: The ECLIPSE study aimed to evaluate the feasibility and efficacy of cryoablation (CA) for local tumor control in patients with pulmonary metastatic disease in 5 years of follow-up. METHODS: ECLIPSE was a prospective, multicenter, single-arm study that included patients treated with CA if they had one to five metastatic lung tumors, each with a diameter of less than or equal to 3.5 cm. Patients were followed up in the course of 5 years. The primary end point was local tumor control, both per tumor and per patient; secondary end points included cancer-specific survival, overall survival, and quality of life (QoL). QoL was evaluated using the Karnofsky Performance Score, the Eastern Cooperative Oncology Group performance score, and the Short Form-12 health survey. RESULTS: The study included 40 patients across four sites (three in United States and one in Europe). A total of 60 metastatic pulmonary tumors were treated with 48 CA procedures. Overall local tumor control rates were 87.9% (29 of 33) and 79.2% (19 of 24) per tumor, 83.3% (20 of 24) and 75.0% (15 of 20) per patient, at 3 and 5 years, respectively. A total of five treated patients had local progression throughout the duration of the study. Disease-specific survival rate was 74.8% at 3 years and 55.3% at 5 years, whereas overall survival at 3 and 5 years was 63.2% and 46.7%, respectively. Patient QoL scores did not reach statistical significance. CONCLUSIONS: CA is an effective means of long-term local tumor control in patients with metastatic pulmonary tumors.","journal":"Journal of Thoracic Oncology","year":2021,"id":154902,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":61,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7166,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":656395,"name":"David A. Woodrum","orcid":"0000-0002-5914-2420","position":1,"is_corresponding":false},{"id":656396,"name":"Lambros Tselikas","orcid":"0000-0002-8878-4916","position":2,"is_corresponding":false},{"id":326543,"name":"Fereidoun Abtin","orcid":"0000-0003-2927-0883","position":3,"is_corresponding":false},{"id":385858,"name":"Peter J. Littrup","orcid":"0000-0002-7760-2988","position":4,"is_corresponding":false},{"id":656397,"name":"Frédèric Deschamps","orcid":"0000-0002-6015-4349","position":5,"is_corresponding":false},{"id":316713,"name":"Robert D. Suh","orcid":"0000-0001-7872-9967","position":6,"is_corresponding":false},{"id":656398,"name":"Hussein D. Aoun","orcid":"0000-0001-6817-7919","position":7,"is_corresponding":false},{"id":286371,"name":"Matthew R. Callstrom","orcid":"0000-0001-5505-1882","position":8,"is_corresponding":false},{"id":656394,"name":"Thierry de Baère","orcid":"0000-0002-4556-7663","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-18T23:43:59.154159Z","pmid":"34384914","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}